Cresco Labs (OTCMKTS:CRLBF) Upgraded by Ventum Cap Mkts to Strong-Buy

Ventum Cap Mkts upgraded shares of Cresco Labs (OTCMKTS:CRLBF) to a strong-buy rating in a research note published on Friday morning, Zacks.com reports. Ventum Cap Mkts also issued estimates for Cresco Labs’ Q3 2024 earnings at ($0.01) EPS, Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at ($0.16) EPS and FY2025 earnings at ($0.03) EPS.

CRLBF has been the subject of a number of other reports. Wedbush upped their price target on shares of Cresco Labs from $2.50 to $3.00 and gave the company an outperform rating in a report on Thursday, May 16th. Roth Capital raised shares of Cresco Labs from a hold rating to a strong-buy rating in a research report on Friday. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Cresco Labs in a research report on Thursday, May 16th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Buy and a consensus target price of $2.63.

Cresco Labs Trading Down 4.0 %

OTCMKTS CRLBF traded down $0.06 on Friday, hitting $1.56. 331,991 shares of the stock were exchanged, compared to its average volume of 820,367. Cresco Labs has a 52-week low of $1.00 and a 52-week high of $2.77. The company has a debt-to-equity ratio of 1.57, a current ratio of 1.36 and a quick ratio of 0.89. The company has a market capitalization of $761.50 million, a price-to-earnings ratio of -3.32 and a beta of 1.86. The company’s 50-day moving average price is $1.64 and its two-hundred day moving average price is $1.88.

Cresco Labs (OTCMKTS:CRLBF) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.15). The company had revenue of $184.36 million for the quarter, compared to analysts’ expectations of $184.26 million. Cresco Labs had a negative net margin of 20.32% and a negative return on equity of 6.78%. Research analysts predict that Cresco Labs will post -0.03 EPS for the current year.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.